Physician profile
Patrick H Friedli
NPI 1255341046
$5,053.00
in general payments reported to CMS, 2019-2025
41 companies · $680 in 2025
The $680 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $524 · 2021: $775 · 2022: $1,035 · 2023: $750 · 2024: $636 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $820.62 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $647.22 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $591.78 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $412.96 | 2021-2025 | |
| Pfizer INC. | $292.92 | 2019-2025 | |
| Astellas Pharma US INC | $262.70 | 2019-2024 | Veozah |
| Supernus Pharmaceuticals, INC. | $214.03 | 2021-2024 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.36 | 2019-2022 | |
| Lilly USA, LLC | $187.50 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $149.53 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Amgen INC. | $139.29 | 2019-2025 | Evenity, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $127.51 | 2019-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $114.97 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $63.65 | 2019 | |
| Dexcom, INC. | $61.28 | 2021-2023 | Dexcom G6 Transmitter |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Friedli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.